IBRX Stock Surges 179% With A 11-day Winning Spree On 700% Revenue Growth
ImmunityBio (IBRX) – a developer of immunotherapies and vaccines for cancer and infections. – hit 11-day winning streak, with cumulative gains over this period amounting to a 179%. The company market cap has surged by about $3.4 Bil over the last 11 days, and currently stands at $5.2 Bil.
The stock has YTD (year-to-date) return of 178.8% compared to 1.4% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity, or a trap.
What Triggered The Rally?
[1] Anktiva’s 700% YoY Revenue Growth
- Get Paid 9.0% to Buy INTU at a 30% Discount – Here’s How
- What Could Set Palantir Technologies Stock on Fire
- Amazon.com Stock on the Edge: 3 Threats You Need to Know
- Cash Machine Trading Cheap – Webull Stock Set to Run?
- Visa Stock Pullback: A Chance to Ride the Uptrend
- McDonald’s Stock Pays Out $79 Bil – Investors Take Note
- $113 million in preliminary net product revenue for 2025
- 431% revenue growth for Q4 2025 vs Q4 2024
- Impact: Stock price surged 39.75% in one day, Trading volume 1,254% above average
[2] Analyst ‘Buy’ Rating & Price Target Hike
- D. Boral Capital reaffirmed ‘Buy’ rating with a $24 price target
- Multiple analysts issued ‘Strong Buy’ consensus ratings
- Impact: Increased investor confidence, Reinforcement of bullish outlook
Opportunity or Trap?
Below is our take on valuation.
There are only a couple of things to fear in IBRX stock given its overall Moderate operating performance and financial condition. But keeping in mind its Very High valuation, we think that the stock is Unattractive (For details, see Buy or Sell IBRX).
But here is the real interesting point.
You are reading about this 179% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has flagged 5 new opportunities that haven not surged yet.
Returns vs S&P 500
The following table summarizes the return for IBRX stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | IBRX | S&P 500 |
|---|---|---|
| 1D | 39.7% | -0.1% |
| 11D (Current Streak) | 178.8% | 1.4% |
| 1M (21D) | 155.6% | 2.1% |
| 3M (63D) | 118.2% | 4.7% |
| YTD 2026 | 178.8% | 1.4% |
| 2025 | -22.7% | 16.4% |
| 2024 | -49.0% | 23.3% |
| 2023 | -1.0% | 24.2% |
However, big gains can follow sharp reversals – but how has IBRX behaved after prior drops? See IBRX Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 102 S&P constituents with 3 days or more of consecutive gains and 49 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 38 | 16 |
| 4D | 17 | 11 |
| 5D | 22 | 12 |
| 6D | 0 | 5 |
| 7D or more | 25 | 5 |
| Total >=3 D | 102 | 49 |
Key Financials for ImmunityBio (IBRX)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0.6 Mil | $14.7 Mil |
| Operating Income | $-361.4 Mil | $-344.2 Mil |
| Net Income | $-583.2 Mil | $-413.6 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $26.4 Mil | $32.1 Mil |
| Operating Income | $-71.3 Mil | $-55.6 Mil |
| Net Income | $-92.6 Mil | $-67.3 Mil |
While IBRX stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.